Male Reproductive Health Panel (MRH)

The Male Reproductive Health (MRH) panel, which includes the SCFA, can help minimize the time, emotional and financial cost of ART attempts at pregnancy while maximizing your live birth rate. Standard semen analysis provides minimal information on a patient's male factor issues that are negatively affecting Assisted Reproductive Technology (ART) attempts at pregnancy. 
 
In order to provide advanced sperm testing that goes beyond standard semen analysis providing clinically significant results, a Male Reproductive Health (MRH) Panel was developed by David B. Brown, Ph.D., President and CEO of Male Fertility Diagnostics, LLC, Fort Lauderdale, Florida and is offered exclusively through Unilab.
 

The Male Reproductive Health Panel (MRHP) was developed by David B. Brown who also determined the performance characteristics.  The MRHP has not been cleared or approved by the US Food and Drug Administration (FDA).  FDA does not require these tests to go through premarket FDA review. This panel of tests is used for clinical purposes.  It should not be regarded as investigational or for research.  The MRHP has been performed commercially for over 11 years by Male Fertility Diagnostics, LLC in partnership with UniLab of Dade, Inc. Both laboratories are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical aboratory testing. 

 
*United States Patent No.:  US 9,157,909 B2: "Male Reproductive Health Panel and UsesThereof." Issued: October 13, 2015. Inventor: David B. Brown